about
Evaluation of current cancer immunotherapy: hemato-oncologyAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisTranslocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia.Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors.Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.Minimal residual disease in acute myeloid leukaemiaBack to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Next generation MRD.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Clinical and biological predictors of outcome following relapse of CML post-allo-SCTCurrent Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCTIdentification of novel microRNA signatures linked to acquired aplastic anemia.CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantationPrecision medicine for acute myeloid leukemiaPersonalized therapy for acute myeloid leukemia.Repair of impaired pulmonary function is possible in very-long-term allogeneic stem cell transplantation survivors.Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events.Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Reprint of: Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.Accurate Medicine: Indirect Targeting of NPM1-Mutated AML.Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Haplo, we have a problem.Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.Are medical schools fit for graduates?Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell TransplantationMinimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.Immunological effects of hypomethylating agents.When the Minimal Becomes Measurable.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using α3 Domain Mutants of MHC Class I/Peptide ComplexThe structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: Steric hindrance influences TCR allo-recognitionCytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeLeukaemia risk associated with low-dose radiation
P50
Q27006179-2E73C18D-1AA5-4A11-A25C-1F4A66A11828Q28087291-3ED7AB88-2443-4C06-8667-DCF8B9797E47Q30234914-9CD35EB7-9854-40F6-800D-DDA78BA731ACQ33734872-54BDA5CA-B289-4DA7-9EBA-6A389CEEACEAQ33815986-C4231032-C44A-4225-8AAE-FDC4B7CBCF8BQ33846627-7DF66C26-6FD6-4935-91E3-39D5409A29DDQ33892358-3F27E534-75E7-4DA6-ACDB-77201B31009CQ34111301-6DB4C383-967B-4026-85C9-D98F54ED2FACQ34134762-209378A1-3237-407C-AA83-AB28FAF40198Q34179265-A4591B03-3FB4-479C-8BCD-30F2F215E969Q34380489-08F69085-775D-4B3A-8FB6-17BA717356BFQ34406955-1BECBE84-3672-4E02-BAF2-AF81A83EAF61Q34980976-79DC5F30-03B8-4EF1-A11C-A5175D435C54Q35054717-5707F1DE-08C4-4947-9D34-8F2001D8F1FCQ35546759-A49B5FD2-D370-4386-AB97-DF25EAC51E53Q35582360-1B7850D2-608F-4E5B-99DC-5D704DF9778BQ36337576-EE1E154F-B642-4CC2-9189-8B20D52A5702Q36403184-9E206FB4-32A0-4D77-89C6-DEA2E8721EB0Q36934758-D32B25E0-1AE7-47B0-9397-314C527EDA81Q37432301-2938959C-5A8D-4A60-AD30-4935BF9FE8E6Q37570160-1BA4CA05-960B-499C-A75B-2BCF075A5C2FQ37593798-44269B74-093B-4323-9BE6-A95D2FDA47F3Q38364283-6B65D864-6467-4234-9840-B42A975DAAB8Q39132424-527D0464-8AD3-4158-A203-265F83C67C9BQ39258834-6444B0A4-D559-46A4-91EE-9778C10EAFEDQ40794740-FC9226C0-AEC3-4600-9AD2-180732227252Q41636372-8716E1B4-057A-4741-B229-DE9001054D90Q41674738-ED676E6E-D5B8-4837-BEE4-FDCFE72AE07EQ42101234-1CC6C1FF-3C52-4AD7-ABB7-EF8BB19E88D2Q42559107-EB1B3967-7947-42AC-A086-097617BA72F7Q42671640-95B4542A-1935-40EC-83DE-47AA18A442E6Q42711146-EDDE340D-ACD1-4A41-8E1D-9D432039C663Q47734674-B6C6CC26-FE5F-4207-A3BD-BCCAEBD3939AQ48229616-649EBE12-A3CE-4AB4-ADD2-8FF7F36D25EBQ54350804-242F788C-57FB-4B40-A007-5928940BFCCBQ54956859-0A66B788-B452-4EC8-961B-BC60F146E90BQ56876472-6F38EF4C-A320-40A9-9D59-EF0B898E31CEQ56914419-345C7D7E-45D4-4170-B777-60056A13AB71Q59342675-9622EEA1-3210-4A33-B18E-01F83532F99DQ59342676-D3147831-2CB1-435A-95B5-8FBE95046FF9
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher S Hourigan
@ast
Christopher S Hourigan
@en
Christopher S Hourigan
@es
Christopher S Hourigan
@nl
type
label
Christopher S Hourigan
@ast
Christopher S Hourigan
@en
Christopher S Hourigan
@es
Christopher S Hourigan
@nl
altLabel
Christopher Hourigan
@en
prefLabel
Christopher S Hourigan
@ast
Christopher S Hourigan
@en
Christopher S Hourigan
@es
Christopher S Hourigan
@nl
P106
P1153
55884808500
6507867424
P21
P31
P496
0000-0002-6189-8067